New hope for advanced cancer patients: JR8603 trial begins
NCT ID NCT06783569
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 35 times
Summary
This study tests a new drug called JR8603 in people with advanced solid tumors (like stomach or colorectal cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 94 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heiljiang Province, 150040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Liaoning Cancer Hospital
RECRUITINGShenyang, Liaoning, 110042, China
Contact
Conditions
Explore the condition pages connected to this study.